Perlecan has also been implicated in the pathophysiology of non-developmental genetic musculoskeletal diseases, such as sarcopenia and OA (Kaneko et al., 2013; Wang et al., 2014; Gubbiotti et al., 2017). This evidence concerns the gene HSPG2 and musculoskeletal system disorder.